kr18.50
2.94%
Stockholm, Sep 24, 05:29 pm CEST. Closed.
ISIN
SE0002485979
Symbol
GENO

Genovis Stock price

kr18.50
-1.50 7.50% 1M
+2.34 14.48% 6M
-2.75 12.94% YTD
-4.25 18.68% 1Y
-28.25 60.43% 3Y
-45.10 70.91% 5Y
+16.04 652.03% 10Y
-171.50 90.26% 20Y
Stockholm, Closing price Thu, Sep 24 2026
-0.56 2.94%

Is Genovis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
kr1.3b
Enterprise Value
kr1.2b
Net debt
positive
Cash
kr157.2m
Shares outstanding
67.5m
Valuation (TTM | estimate)
P/E
61.5
P/S
9.4 | 8.2
EV/Sales
8.8 | 7.7
EV/FCF
23.2
P/B
4.1
Financial Health
Equity Ratio
71.8%
Return on Equity
8.7%
ROCE
4.8%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
kr135.6m | kr155.0m
EBITDA
kr33.6m
EBIT
kr18.7m
Net Income
kr20.5m
Free Cash Flow
kr51.2m
Growth (TTM | estimate)
Revenue
11.2% | 20.2%
EBITDA
-28.9%
EBIT
-49.8%
Net Income
-24.0%
Free Cash Flow
108.3%
Margin
Gross
89.4%
EBITDA
24.8%
EBIT
13.8%
Net
15.1%
Free Cash Flow
37.8%
More
EPS
kr0.3
FCF per Share
kr0.8
Short interest
-
Employees
36
Rev per Employee
kr3.6m

Genovis Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Genovis forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Genovis forecast:

Buy
86%
Hold
14%

Financial data from Genovis

Jun '26
+/-
%
136 136
11% 11%
100%
- Direct Costs 14 14
30% 30%
11%
121 121
20% 20%
89%
- Selling and Administrative Expenses 52 52
19% 19%
38%
- Research and Development Expense - -
-
-
34 34
29% 29%
25%
- Depreciation and Amortization 15 15
49% 49%
11%
EBIT (Operating Income) EBIT 19 19
50% 50%
14%
Net Profit 21 21
24% 24%
15%

In millions SEK.

Don't miss a Thing! We will send you all news about Genovis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genovis AB engages in the research and development of enzyme products. Its product portfolio includes SmartEnzymes, which offers to pharmaceutical and medical device industries tools that facilitate the development of new treatment methods and diagnostics. The company was founded by Inga Sarah Maria Fredriksson in 1999 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Mr. Olsson
Employees 36
Founded 1999
Website www.genovis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today